, Tracking Stock Market Picks
Enter Symbol:
Celldex Therapeutics, Inc. (CLDX) [hlAlert]

up 35.75 %

Celldex Therapeutics, Inc. (CLDX) rated Outperform by Leerink Swann

Posted on: Wednesday,  Mar 6, 2013  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Celldex Therapeutics, Inc. (NASDAQ: CLDX) on 03/06/2013, when the stock price was $11.13.
Since then, Celldex Therapeutics, Inc. has gained 35.76% as of 01/25/2016's recent price of $15.11.
If you would have followed this Leerink Swann 's recommendation on CLDX, you would have gained 35.75% of your investment in 1055 days.

Celldex Therapeutics, Inc. (Celldex) is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. The Company?s immunotherapy platform includes a portfolio of monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create disease-specific drug candidates. Its collaborations include the commercialization of an oral human rotavirus vaccine and the development of oncology and infectious disease vaccines. On October 1, 2009, Celldex acquired CuraGen Corporation.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/6/2013 8:25 AM Buy
as of 12/13/2013
1 Week down  -12.94 %
1 Month down  -12.03 %
3 Months down  -5.77 %
1 YTD up  102.33 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy